{
  "id": "multiple-myeloma-regimens-main",
  "display_name": "Multiple Myeloma Regimen Margins",
  "cohort": "Multiple Myeloma, Relapsed/Refractory, by Regimen (2024–2025)",
  "insight_type": "Margin Analysis",
  "summary": "Daratumumab-based regimens deliver 42% higher margins than other RRMM treatments. A 15% utilization increase could yield $385,000/year in additional margin.",
  "chart": {
    "type": "bar",
    "unit": "regimen",
    "data": [
      { "name": "Dara-Rd", "value": 82, "gap": 32, "highlight": true },
      { "name": "Dara-Vd", "value": 68, "gap": 18, "highlight": false },
      { "name": "Dara-KPd", "value": 75, "gap": 25, "highlight": false },
      { "name": "KRd", "value": 58, "gap": 8, "highlight": false },
      { "name": "Vd", "value": 50, "gap": 0, "highlight": false },
      { "name": "Rd", "value": 45, "gap": -5, "highlight": true }
    ],
    "benchmark": 50,
    "nccn_target": 50
  },
  "financial_impact": {
    "annual_opportunity": "$385,000/year",
    "math": "$385,000/year = 15% increase × 35 patients × $73,000 margin difference"
  },
  "clinical_impact": {
    "description": "Daratumumab-based regimens provide substantial clinical benefits in relapsed/refractory multiple myeloma.",
    "metrics": [
      {
        "type": "PFS",
        "value": "+18.4 months",
        "description": "Improved progression-free survival with Dara-Rd"
      },
      {
        "type": "OS",
        "value": "+13.3 months",
        "description": "Overall survival benefit vs. non-Daratumumab regimens"
      },
      {
        "type": "ORR",
        "value": "+31%",
        "description": "Higher objective response rate"
      },
      {
        "type": "MRD",
        "value": "+24%",
        "description": "Better MRD negativity rates"
      },
      {
        "type": "ToT",
        "value": "+52%",
        "description": "Longer time on treatment"
      }
    ],
    "quantitative": "+18.4 months PFS"
  },
  "peer_comparison": {
    "description": "Your practice uses Daratumumab-based regimens in only 34% of eligible RRMM patients, compared to 55% among peers. This represents a $450,000/year margin opportunity.",
    "peer_benchmark": 55,
    "financial_impact": {
      "annual_opportunity": "$450,000/year",
      "math": "$450,000/year = 21% increase × 29 patients × $73,000 margin difference"
    },
    "action_steps": [
      {
        "text": "Schedule RRMM regimen selection discussion with oncology team",
        "icon": "users"
      },
      {
        "text": "Develop Daratumumab-based regimen clinical pathway",
        "icon": "document"
      },
      {
        "text": "Implement RRMM regimen margin dashboard by provider",
        "icon": "chart"
      },
      {
        "text": "Create automated alerts for eligible RRMM patients",
        "icon": "alert"
      }
    ]
  },
  "weighted_score": 92,
  "action_steps": [
    {
      "text": "Identify RRMM patients eligible for regimen optimization",
      "icon": "flag"
    },
    {
      "text": "Update order sets to prioritize Daratumumab-based regimens",
      "icon": "document"
    },
    {
      "text": "Implement regimen-specific financial counseling",
      "icon": "clipboard"
    },
    {
      "text": "Analyze supportive care impact on total regimen costs",
      "icon": "chart-line"
    }
  ],
  "suggestions": [
    {
      "text": "Optimize prior authorization processes for Daratumumab regimens",
      "icon": "document"
    },
    {
      "text": "Develop infusion center capacity planning for longer infusions",
      "icon": "chart"
    }
  ],
  "drilldowns": [
    {
      "label": "View by Provider",
      "cohort": "Multiple Myeloma, RRMM, by Provider Regimen Selection",
      "jsonFile": "multiple-myeloma-by-provider.json",
      "drilldownLevel": 1
    },
    {
      "label": "Compare Payer Coverage",
      "cohort": "Multiple Myeloma, RRMM, by Payer Regimen Coverage",
      "jsonFile": "multiple-myeloma-by-payer.json",
      "drilldownLevel": 1
    },
    {
      "label": "Margin Detail Analysis",
      "cohort": "Multiple Myeloma, RRMM, Regimen Margin Components",
      "jsonFile": "multiple-myeloma-regimen-margins.json",
      "drilldownLevel": 1
    }
  ]
} 